Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience
Turkish Journal Of Medical SciencesPeer ReviewedNur Soyer +102018Journals
In Turkey, lenalidomide plus dexamethasone (RD) has been used to treat relapsed/refractory multiple myeloma (RRMM) since 2010. This retrospective, single-center study evaluated the efficacy and tolerability of RD in patients with RRMM between October 2010 and June 2016.
The content you want is available to Zendy users.
Already have an account? Sign inHaving issues? Contact support